Job title: Global Product General Manager, Oncology (KRAS Franchise | Sotorasib)
Sanket currently serves as General Manager of Amgen’s investigational KRAS franchise in Oncology, including first-in-class G12C inhibitor Sotorasib in solid tumors, the first molecule to ‘drug the target’ in a 40-year quest. He has overall accountability for strategy, investments and operational execution to launches globally, leading it from first-in-human stage. Sanket oversees cross-functional KRAS teams spanning discovery, clinical/medical, supply, commercialization, and partnerships. Prior, he was GM of Amgen’s neuroscience pipeline, held several leadership roles in marketed and pipeline commercial oncology, and transformation and strategy executive responsibilities in Corporate and R&D functions.
Pre-Amgen, Sanket was most recently Chief Strategy/Business Officer at Relsys International up to its acquisition by Oracle Health Sciences. He started his career with leading consulting firms including Accenture and Deloitte in Canada, before decamping to Silicon Valley and ultimately SoCal. He holds an MPH from University of Liverpool, MBA from UCLA/Anderson, and MEng from University of Toronto.
Sanket’s driving passion is to push the boundaries of science and healthcare to bring forward new therapies for grievous medical needs and serve patients most in need. He is grateful to have such opportunities. He lives in South Bay LA and loves SoCal’s dynamic yet cool vibe.